Cochlear Implants
by Sara Ashburn-Reed

Hybrid Hearing: Who is a Candidate?

June 29, 2015
Share

The Cochlear™ Nucleus® Hybrid™ Implant System is the only FDA-approved electric-plus-acoustic option available today.

This innovative technology transforms the way hearing loss is treated, allowing adults with high-frequency hearing loss to access critical speech sounds through electrical stimulation combined with natural acoustic hearing.

Hybrid candidates struggle to hear well in noise and will report dissatisfaction with appropriately fit hearing aids. Help them get back what they are missing!Candidacy-Indications

We recommend use of the CNC and AzBio tests for candidacy evaluation. Click here for the pre-operative hearing implant candidate worksheet.

Hybrid is indicated for adult unilateral use only. Cochlear’s Nucleus 6 Sound Processor* is the only sound processor available today with combined electric and acoustic stimulation in a single device. Recipients often elect to continue use of their contralateral hearing aid.

Hear from recipients who use Hybrid Hearing:

* Only approved for use with the Cochlear Nucleus Hybrid Implant

Author

Sara Ashburn-Reed

Sara Ashburn-Reed is the Senior Manager of Marketing and Clinical Strategy for Cochlear Americas where she is responsible for the region's professional clinical information and insights. Sara enjoys engaging with Cochlear's professional partners and broadly communicating key research, industry trends and emerging data. Do you have topics you would like to learn more about? Would you like to guest-author a ProNews Blog? Would you like to be interviewed about your research? Reach out to Sara at: sashburn-reed@cochlear.com

View all posts

Related Posts
Cochlear Case Studies

Cochlear Case Studies: Electrode selection

July 19, 2021

Cochlear Case Studies is a series on Cochlear ProNews that highlights relevant clinical and surgical scenarios surrounding the latest hearing industry topics and research. We’re excited to partner with professionals to highlight their experiences surrounding specific patients.

This first installment features five surgeons, their cases and contributing factors for use of different electrodes:

Use of Slim Straight Electrode with Dr. Daniel Zeitler

Daniel Zeitler, board-certified Otologist/Neurotologist and Skull Base Surgeon at Virginia Mason Medical Center in Seattle, presents a case where the patient had significant right-sided tinnitus along with extensive noise exposure for many years. Due to the inability to completely visualize nor access the round window, the surgeon determined that the silicone sheath of the CI632 would not fit in the small opening making the use of this electrode impossible. Fortunately, the CI622 had been ordered as backup, and the intraoperative decision was made to use the CI622 electrode instead due to its small diameter.

Use of Cochlear Nucleus® Profile™ Plus with Slim 20 Electrode with Dr. Marlan Hansen

Marlan Hansen, MD, is a Professor in the Departments of Otolaryngology-Head and Neck Surgery, Neurosurgery and Molecular Physiology and Biophysics. He presents a young adult male with hearing loss identified at age five. Dr. Hansen elected to use a Nucleus® Profile™ Plus with Slim 20 Electrode (CI624), as the patient presented with aidable low frequency hearing and there was a desire to preserve the structure of the cochlea while providing a full-length electrode option. 

Use of Contour Advance Electrode with Dr. David Friedmann

David Friedmann, MD, MSc, is a neurotologist, cochlear implant surgeon and clinical investigator at NYU Grossman School of Medicine. He presented a middle-aged male with a long history of bilateral otosclerosis first diagnosed in his 20’s when he began wearing hearing aids.  He chose to use Contour Advance™ (CI512) for the stiffness of the stylet and perimodiolar preference.

Benefit of cochlear implantation with use of Contour Advance® Electrode

Lisa Bell, AuD, and Sujana Chandrasekhar, MD, FACS, from ENT and Allergy Associates presented a middle-aged female with developmental delays. The Cochlear™ Nucleus® Profile™ with Contour Advance® Electrode (CI512) was selected for implantation due to the normal anatomy determined via pre-operative CT scan. Read more on the clinical and surgical perspective of this case.

CI632 trauma case with Dr. Sarah Mowry

Sarah Mowry, MD at University Hospitals, presented a 52-year-old male who had sustained direct head trauma after falling down a flight of stairs. She chose the CI632 for its perimodiolar position, MRI compatibility and slim profile to help minimize trauma in this already traumatized cochlea.  

To hear more , listen to our Cochlear Case Studies surgeon panel webinar!

Newly published: First-ever global consensus on use of cochlear implants in adults

September 1, 2020

The first global consensus on the use of cochlear implants for the management of bilateral moderate to profound, or moderate sloping to profound hearing loss in adults was published online on August 27, 2020 in JAMA Otolaryngology Head and Neck Surgery.1

According to Professor Craig Buchman, Chair of the Consensus Delphi Process and Head of Otolaryngology –Washington University School of Medicine, the consensus is a major landmark in the treatment of hearing loss.

“The International Consensus Paper is the culmination of a systematic review and a consensus process, put together to inform steps towards establishing clear and consistent guidelines, and best practices for the evaluation and management of patients with moderate to profound, or worse, sensorineural hearing loss, including cochlear implants and their aftercare, so they can reach their optimal hearing outcome and attain the best quality of life.”

The paper covers seven categories across the whole care path.

Representatives from seven cochlear implant user and professional advocacy organizations provided comments throughout the process. One of the representatives, Barbara Kelley, President of the Hearing Loss Association of America described the consensus as a call to action for those involved in organising, delivering and receiving hearing health care.

“Globally, for up to 53 million hard of hearing people hearing aids might not be enough. The consensus empowers them to explore their opportunities with cochlear implant treatment” added Barbara Kelley.

Conservative estimates suggest that worldwide, only 1 in 20 adults who could benefit from a cochlear implant have one.2,3

About the consensus method

The process was guided by the non-voting Chair, Professor Buchman, supported by four voting steering committee members. The Delphi panel comprised of an additional 26 experts in the field of CI use, including audiologists and ear, nose and throat specialists across 13 countries. The seven representatives from international hard of hearing, CI user and professional advocacy organisations provided comments throughout the process.

Learn more

Read the scientific publication.

Register to attend the recorded Audiology Online course featuring Delphi panel members René Gifford, PhD and Terry Zwolan, PhD.

Visit the online professional portal with summaries of the evidence supporting the global consensus as well as more information on the CAPAC  www.adulthearing.com

References

  1. Buchman et al. JAMA Otolaryngology Head and Neck Surgery1.2020
  1. Sorkin DL. Cochlear implantation in the world’s largest medical device market: utilization and awareness of cochlear implants in the United States. Cochlear implants international. 2013 Mar 1;14(sup1):S12-4.
  2. De Raeve L. Cochlear implants in Belgium: Prevalence in paediatric and adult cochlear implantation. European annals of otorhinolaryngology, head and neck diseases. 2016 Jun 1;133:S57-60.

The Delphi process and medical writing support have been funded by Advanced Bionics, Cochlear Ltd, MED-EL and Oticon Medical. The funding organizations did not contribute to the design, facilitation or content of the Delphi consensus process. 

Cochlear logo - white

©Cochlear Limited 2024. All rights reserved. ACE, Advance Off-Stylet, AOS, Ardium, AutoNRT, Autosensitivity, Baha, Baha SoftWear, BCDrive, Beam, Bring Back the Beat, Button, Carina, Cochlear, 科利耳, コクレア, 코클리어, Cochlear SoftWear, Contour, コントゥア, Contour Advance, Custom Sound, DermaLock, Freedom, Hear now. And always, Hugfit, Human Design, Hybrid, Invisible Hearing, Kanso, LowPro, MET, MP3000, myCochlear, mySmartSound, NRT, Nucleus, Osia, Outcome Focused Fitting, Off-Stylet, Piezo Power, Profile, Slimline, SmartSound, Softip, SoundArc, True Wireless, the elliptical logo, Vistafix, Whisper, WindShield and Xidium are either trademarks or registered trademarks of the Cochlear group of companies. The names of actual companies and products mentioned herein may be the trademarks of their respective owners.

 

This material is intended for health professionals. If you are a consumer, please seek advice from your health professional about treatments for hearing loss. Outcomes may vary, and your health professional will advise you about the factors which could affect your outcome. Always read the instructions for use. Not all products are available in all countries. Please contact your local Cochlear representative for product information.

 

Cochlear ProNews is monitored Monday through Friday, excluding some holidays. Questions and inquiries submitted over the weekends or holidays may see a delay in response. For immediate assistance please contact us directly. You are solely responsible for your interactions with other members of our Websites. Cochlear reserves the right, but has no obligation, to monitor disputes or communications between you and other members of our Websites. For a full list of Cochlear’s terms of use, click here.